| acellular vaccine | <immunology, pharmacology, virology> Vaccine consisting of antigenic parts of cells. (13 Nov 1997) |
|---|---|
| adjuvant vaccine | A vaccine that contains an adjuvant; most often the antigen (immunogen) is included in a water-in-oil emulsion (Freund incomplete type adjuvant), or is adsorbed onto an inorganic gel (alum, aluminum hydroxide or phosphate). (05 Mar 2000) |
| aqueous vaccine | A vaccine having a liquid vehicle (e.g., physiological salt solution) as distinguished from an emulsion. (05 Mar 2000) |
| attenuated vaccine | Live pathogens that have lost their virulence but are still capable of inducing a protective immune response to the virulent forms of the pathogen, e.g., Sabin polio vaccine. (05 Mar 2000) |
| autogenous vaccine | A vaccine made from a culture of the patient's own bacteria. (05 Mar 2000) |
| bacillus Calmette-Guerin vaccine | <drug> Live attenuated vaccine for tuberculosis. For groups and health care workers in high endemic areas. Not to be given to individuals with HIV infection. (15 Nov 1997) |
| BCG vaccine | <drug> Live attenuated vaccine for tuberculosis. For groups and health care workers in high endemic areas. Not to be given to individuals with HIV infection. (15 Nov 1997) |
| brucella strain 19 vaccine | A live bacterial vaccine prepared from an attenuated variant strain of Brucella abortus (strain 19); used for vaccinating cattle against brucellosis. (05 Mar 2000) |
| brucella vaccine | A bacterial vaccine for the prevention of brucellosis in man and animal. Brucella abortus vaccine is used for the immunization of cattle, sheep, and goats. (12 Dec 1998) |
| Calmette-Guerin vaccine | <drug> Live attenuated vaccine for tuberculosis. For groups and health care workers in high endemic areas. Not to be given to individuals with HIV infection. (15 Nov 1997) |
| rabies vaccine | An inactivated virus vaccine, used for preexposure immunization to persons at high risk of exposure, e.g., veterinarians, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis. The official preparation is human diploid cell vaccine produced from rabies virus grown in cultures of human diploid embryo lung cells and inactivated with propriolactone. It has a much lower incidence of adverse reactions than the previously used duck embryo vaccine. (12 Dec 1998) |
| vaccine | <pharmacology> A suspension of attenuated or killed microorganisms (bacteria, viruses or rickettsiae), administered for the prevention, amelioration or treatment of infectious diseases. Origin: L. Vaccinus (18 Nov 1997) |
| vaccine bodies | Old term pertaining to intracellular body's that were erroneously thought to be forms in the life cycle of a protozoan organism, Cytorrhyctes vaccinae, postulated to be the causal agent of vaccinia. (05 Mar 2000) |
| vaccine, flu | The flu (influenza) vaccine is recommended for persons at high risk for serious complications from influenza infection, including everyone 65 or over; people with chronic diseases of the heart, lung or kidneys, diabetes, immunosuppression, or severe forms of anaemia; residents of nursing homes and other chronic-care facilities, children and teenagers taking aspirin therapy (and who may therefore be at risk for developing reye syndrome after an influenza infection), and those in close or frequent contact with anyone at high risk. Persons with an allergy to eggs should not receive influenza vaccine. (12 Dec 1998) |
| vaccine, influenza | See Vaccine, flu. Vaccination, dtap: like dpt, dtap protects from diphtheria, pertussis (whooping cough) and tetanus. Dtap is the same as dtp, except that it contains only acellular pertussis vaccine which is thought to cause fewer of the minor reactions associated with immunization and is also probably less likely to cause the more severe reactions occasionally seen following pertussis vaccination. Dtap is currently recommended only for the shots given at 18 months and 4-6 years of age. Vaccination, dt: dt (diphtheria and tetanus) vaccine does not protect from pertussis and is usually reserved for individuals who have had a significant adverse reaction to a dpt shot or who have a personal or family history of a seizure disorder or brain disease. (12 Dec 1998) |